Visionquest Biomedical: VisionQuest Biomedical's EyeStar Passes the 30,000-Patient Milestone for Diabetic Retinopathy Screening Using Artificial Intelligence

(marketscreener.com) VisionQuest Biomedical Inc. announces that the company has screened over 30,000 patients for diabetic retinopathy at the Clínicas del Azúcar in Mexico using the EyeStar artificial intelligence software. The EyeStar AI system screens patients for diabetic retinopathy and macular edema, conditions that lead to vision loss and...https://www.marketscreener.com/news/VisionQuest-Biomedical-s-EyeStar-Passes-the-30-000-Patient-Milestone-for-Diabetic-Retinopathy-Screen--31108048/?utm_medium=RSS&utm_content=20200812